|
Brexpiprazole ( ; brand name Rexulti , previously known as OPC-34712) is a novel atypical antipsychotic drug. It is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). The drug received FDA approval on July 13, 2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression.〔(【引用サイトリンク】website=FDA Newsroom )〕 Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).〔(【引用サイトリンク】url=http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=6821030 )〕 The drug was developed by Otsuka and Lundbeck, and is considered to be a successor of Otsuka's top-selling antipsychotic agent aripiprazole (brand names: Abilify, Aripiprex). Otsuka's US patent on aripiprazole expired on October 20, 2014;〔Patent 〕 however, due to a pediatric extension, a generic will become available in the near future. == Partnership with Lundbeck == In November 2011, Otsuka and Lundbeck have announced a global alliance.〔(【引用サイトリンク】url=http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=622993 )〕 Lundbeck has given Otsuka an upfront payment of $200 million, and the deal includes development, regulatory and sales payments, for a potential total of $1.8 billion. Specifically for OPC-34712, Lundbeck will obtain 50% of net sales in Europe and Canada and 45% of net sales in the US from Otsuka. The partnership has been presented by Otsuka to its investors as a good fit for several reasons:〔(【引用サイトリンク】url=http://www.net-ir.ne.jp/e-pre/45781111e/parts/material0.pdf )〕 * Geographic strategy: Otsuka in Japan, Asia, US; Lundbeck in Europe, South America and emerging markets * Research strategy: Otsuka has knowledge in antipsychotics, Lundbeck in anti-depressant and anxiolytic. * CNS strategy: Otsuka has a robust portfolio in next-generation CNS drugs, while Lundbeck covers a wide range of CNS conditions from Alzheimer's to schizophrenia. * Similar corporate culture 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Brexpiprazole」の詳細全文を読む スポンサード リンク
|